Spruce Biosciences 2025 net loss narrows, secures $50 mln funding

Reuters03-09
<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> 2025 net loss narrows, secures $50 mln funding

Overview

  • Biopharmaceutical firm's net loss for 2025 decreased compared to 2024

  • Company secured up to $50 mln in growth capital from Avenue Capital

  • Company appointed Dale Hooks as Chief Commercial Officer

Outlook

  • Spruce Biosciences plans BLA submission for TA-ERT in Q4 2026

  • Company secured $50 mln growth capital for TA-ERT launch

  • Spruce Biosciences aims for accelerated approval of TA-ERT

Result Drivers

  • R&D EXPENSES - Decrease in R&D expenses was due to cessation of tildacerfont development, offset by TA-ERT activities

  • FDA MEETINGS - Positive FDA meetings strengthened confidence in TA-ERT development for MPS IIIB

  • LONG-TERM DATA - Long-term data presented for TA-ERT showed potential as a disease-modifying treatment for MPS IIIB

Company press release: ID:nBwc197VXa

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Net Income

-$38.97 mln

FY Income From Operations

-$36.51 mln

FY Operating Expenses

$36.51 mln

Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Spruce Biosciences Inc is $190.00, about 240.1% above its March 6 closing price of $55.87

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment